212 related articles for article (PubMed ID: 30293700)
1. Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets.
Nazeri E; Gouran Savadkoohi M; Majidzadeh-A K; Esmaeili R
Crit Rev Oncol Hematol; 2018 Nov; 131():102-109. PubMed ID: 30293700
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163019
[TBL] [Abstract][Full Text] [Related]
3. [Inflammation as molecular target in chondrosarcoma].
Kalinski T
Pathologe; 2014 Nov; 35 Suppl 2():249-53. PubMed ID: 25394974
[TBL] [Abstract][Full Text] [Related]
4. Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A.
Hua G; Liu Y; Li X; Xu P; Luo Y
Oncol Rep; 2014 Jun; 31(6):2727-34. PubMed ID: 24789077
[TBL] [Abstract][Full Text] [Related]
5. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Speetjens FM; de Jong Y; Gelderblom H; Bovée JV
Curr Opin Oncol; 2016 Jul; 28(4):314-22. PubMed ID: 27166664
[TBL] [Abstract][Full Text] [Related]
6. What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma?
Palmini G; Marini F; Brandi ML
Molecules; 2017 Mar; 22(3):. PubMed ID: 28272374
[TBL] [Abstract][Full Text] [Related]
7. New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.
Monderer D; Luseau A; Bellec A; David E; Ponsolle S; Saiagh S; Bercegeay S; Piloquet P; Denis MG; Lodé L; Rédini F; Biger M; Heymann D; Heymann MF; Le Bot R; Gouin F; Blanchard F
Lab Invest; 2013 Oct; 93(10):1100-14. PubMed ID: 23958880
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment targets in sarcoma: more than just the GIST.
Shoushtari AN; Van Tine BA; Schwartz GK
Am Soc Clin Oncol Educ Book; 2014; ():e488-95. PubMed ID: 24857144
[TBL] [Abstract][Full Text] [Related]
9. Aberrant DNA methylations in chondrosarcoma.
Liu P; Shen JK; Xu J; Trahan CA; Hornicek FJ; Duan Z
Epigenomics; 2016 Nov; 8(11):1519-1525. PubMed ID: 27686001
[TBL] [Abstract][Full Text] [Related]
10. Basic fibroblast growth factor promotes doxorubicin resistance in chondrosarcoma cells by affecting XRCC5 expression.
Hsieh MJ; Huang C; Lin CC; Tang CH; Lin CY; Lee IN; Huang HC; Chen JC
Mol Carcinog; 2020 Mar; 59(3):293-303. PubMed ID: 31916307
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic molecular targets in human chondrosarcoma.
Jamil N; Howie S; Salter DM
Int J Exp Pathol; 2010 Oct; 91(5):387-93. PubMed ID: 21078112
[TBL] [Abstract][Full Text] [Related]
12. Activity of sunitinib in extraskeletal myxoid chondrosarcoma.
Stacchiotti S; Pantaleo MA; Astolfi A; Dagrada GP; Negri T; Dei Tos AP; Indio V; Morosi C; Gronchi A; Colombo C; Conca E; Toffolatti L; Tazzari M; Crippa F; Maestro R; Pilotti S; Casali PG
Eur J Cancer; 2014 Jun; 50(9):1657-64. PubMed ID: 24703573
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of chondrosarcoma.
Jeong W; Kim HJ
J Clin Pathol; 2018 Jul; 71(7):579-583. PubMed ID: 29593061
[TBL] [Abstract][Full Text] [Related]
14. Biological aspects of chondrosarcoma: Leaps and hurdles.
Mery B; Espenel S; Guy JB; Rancoule C; Vallard A; Aloy MT; Rodriguez-Lafrasse C; Magné N
Crit Rev Oncol Hematol; 2018 Jun; 126():32-36. PubMed ID: 29759564
[TBL] [Abstract][Full Text] [Related]
15. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Cleton-Jansen AM; van Beerendonk HM; Baelde HJ; Bovée JV; Karperien M; Hogendoorn PC
Clin Cancer Res; 2005 Nov; 11(22):8028-35. PubMed ID: 16299232
[TBL] [Abstract][Full Text] [Related]
16. Functional roles of CSPG4/NG2 in chondrosarcoma.
Jamil NS; Azfer A; Worrell H; Salter DM
Int J Exp Pathol; 2016 Apr; 97(2):178-86. PubMed ID: 27292772
[TBL] [Abstract][Full Text] [Related]
17. miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism.
Tang XY; Zheng W; Ding M; Guo KJ; Yuan F; Feng H; Deng B; Sun W; Hou Y; Gao L
Drug Des Devel Ther; 2016; 10():571-83. PubMed ID: 26966351
[TBL] [Abstract][Full Text] [Related]
18. Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma.
Roche ME; Lin Z; Whitaker-Menezes D; Zhan T; Szuhai K; Bovee JVMG; Abraham JA; Jiang W; Martinez-Outschoorn U; Basu-Mallick A
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165962. PubMed ID: 32920118
[TBL] [Abstract][Full Text] [Related]
19. Novel strategies for the treatment of chondrosarcomas: targeting integrins.
Chen JC; Fong YC; Tang CH
Biomed Res Int; 2013; 2013():396839. PubMed ID: 24490159
[TBL] [Abstract][Full Text] [Related]
20. The oncogene LRF is a survival factor in chondrosarcoma and contributes to tumor malignancy and drug resistance.
Kumari R; Li H; Haudenschild DR; Fierro F; Carlson CS; Overn P; Gupta L; Gupta K; Nolta J; Yik JH; Di Cesare PE
Carcinogenesis; 2012 Nov; 33(11):2076-83. PubMed ID: 22847180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
